Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT03946878 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Blastoid Variant Mantle Cell Lymphoma
CCND1 Protein Overexpression
CD20 Positive
CD5 Positive
FCER2 Negative
Pleomorphic Variant Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
t(11;14)(q13;q32)

Interventions

DRUG: Acalabrutinib
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]